The development and application of cellular immunotherapy for MS is driven by the need to restore immune tolerance to self-antigens of the CNS (such as myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG)). This evidence concerns the gene OMG and myeloid sarcoma.